The iShares US Pharmaceuticals ETF (IHE) is rated a hold due to fair valuation and increasing short-term challenges. Its portfolio is heavily concentrated, with 43% in Johnson & Johnson and Eli Lilly, and the top 10 holdings making up 76%. Technical indicators show weakening trends, including a recent break of trendline support, suggesting a possible 10% price correction to around $97 by October. Seasonal factors are also unfavorable in September and October, although long-term growth drivers like artificial intelligence remain promising. Investors should be cautious of near-term risks despite the ETF's strong summer performance.
More than 200 companies are actively developing over 240 Alzheimer's disease therapies, with around 20 drugs in late-stage trials and many others in earlier phases. Key players include Eli Lilly, Biogen, Johnson & Johnson, and Eisai, focusing on inno...
Procter & Gamble's stock surged 6% following a quarterly earnings beat with core EPS of $2 and net sales of $23.28 billion, surpassing expectations. The company’s price increases are holding up well, driven by resilient higher-income consumers, thoug...
Johnson & Johnson reported strong pharmaceutical growth with Innovative Medicine up 7.9%, driving optimism for its stock with a 12-month price target of $288.66, an 11.48% upside. However, its MedTech segment showed weak international sales growth an...
Johnson & Johnson has increased its dividend annually for 64 years, yet its stock returns over the past decade were outpaced by the S&P 500 index. While a $1,000 investment in J&J grew to about $2,957 with dividends reinvested, the S&P 500 grew even ...
Johnson & Johnson reported a 96% drop in GAAP net earnings for Q3 due to a one-time legal charge related to talc litigation, but adjusted earnings fell only 7.5%. The company raised its full-year adjusted EPS guidance and maintained a strong dividend...
